<div class="modal hidden">
    <button class="close-btn safety">
        <i class="fas fa-times"></i>
    </button>
    <h4>WHAT WERE THE MOST COMMON ADVERSE EVENTS THROUGHOUT THE ENTIRE TOFACITINIB EXPOSURE PERIOD?</h4>
    <div class="btn-container">
        <button class="modal-btn safety">
            UPPER RESPIRATORY INFECTION, NASOPHARYNGITIS AND NAUSEA
        </button>
        <button class="modal-btn safety">
            UPPER RESPIRATORY INFECTION, HEADACHE AND NASOPHARYNGITIS
        </button>
        <button class="modal-btn safety">
            DISEASE PROGRESSION, JIA FLARE AND UPPER RESPIRATORY INFECTION
        </button>
        <button class="modal-btn safety">
            DISEASE PROGRESSION, UPPER RESPIRATORY INFECTION AND NASOPHARYNGITIS
        </button>
        <div class="result hidden">
            <i class="fas fa-check"></i>
            CORRECT!
        </div>
        <button class="submit safety">
            <i class="fas fa-check"></i>
            SUBMIT
        </button>
    </div>
</div>
<section id="safety" class="section">
    <nav class="desktop">
        <a href="" ui-sref="MOA" class="moa">
            <i class="fas fa-atom"></i>
        </a>
        <a href="" ui-sref="CT" class="ct">
            <i class="fas fa-users"></i>
        </a>
        <a href="" ui-sref="EFFICACY" class="efficacy">
            <i class="fas fa-chart-line"></i>
        </a>
        <a href="" ui-sref="SAFETY" class="safety active">
            <i class="fas fa-exclamation-triangle"></i>
        </a>
        <a href="" ui-sref="DOSING" class="dosing">
            <i class="fas fa-prescription"></i>
        </a>
    </nav>
    <main>
    <div class="top">
        <a href="" ui-sref="LANDING-PAGE"><img src="assets/pfizer-logo.svg" alt="Pfizer Logo"></a>
        <h1>Tofacitinib pcJIA</h1>
    </div>
    <div class="content swiper mySwiper">
        <div class="swiper-wrapper adverse-events">
            <div class="swiper-slide">
                <h3 class="safety-header">ADVERSE EVENTS (FAS - pcJIA, jPsA, ERA)<sup>a</sup></h3>
                <div class="content-container">

                <div class="slide-btns">
                    <a href="" ui-sref="SPECIAL-INTEREST" class="slide-btn safety">AEs OF SPECIAL INTEREST</a>
                </div>
                <div class="img-wrapper">
                <img src="assets/safety/safety-1.svg" class="safety-1" alt="Patients with events" />
                </div>
                </div>
                <div class="footnotes">
                    <ol>
                        <li>Phase 3 safety data include full analysis set ( pcJIA , jPsA , ERA patients included).</li>
                        <li>5 mg BID or equivalent weight based lower dose in patients &lt;40 kg.</li>
                    </ol>
                    <p>BID, twice daily; ERA, enthesitis-related arthritis; FAS, full analysis set; jPsA, juvenile psoriatic arthritis; PBO, placebo; pcJIA, polyarticular course juvenile idiopathic arthritis.</p>
                    <p>1. Data on file. Pfizer, Inc. 2022. 2. Ruperto N. Lancet. 2021;398:1984-1996. 3. XELJANZ/XELJANZ XR/XELJANZ Oral Solution. Prescribing information. Pfizer, Inc. 2021.</p>
                </div>
            </div>
            <div class="swiper-slide common-aes">
                <div class="content-container">
                <h3 class="safety-header">MOST COMMON AEs (&geq;5% OCCURANCE)</h3>
                <div class="img-wrapper">
                    <img src="assets/safety/safety-3.svg" alt="Patients with events chart" />
                </div>
            </div>
            <div class="footnotes">
                <p>“Disease progression” and “JIA flare” (depending on CRF preferred term) refer to a flare according to JIA ACR criteria.
                </p>
                <ol>
                    <li>Part 1  included enrolled patients who received ≥1 dose of study medication (18 week open label run in phase). Patients randomized to Part 2 (26 week double blind phase) received ≥1 dose of study medication reported under received treatment; these analysis sets include patients with pcJIA , PsA , or ERA.</li>
                    <li>5 mg BID or equivalent weight based lower dose in patients &lt;40kg.</li>
                </ol>
                <p>ACR, American College of Rheumatology; BID, twice daily; CRF, case report form; DB, double-blind; ERA, enthesitis-related arthritis; JIA, juvenile idiopathic arthritis; pcJIA, polyarticular course juvenile
                idiopathic arthritis; PsA, psoriatic arthritis; URI, upper respiratory infection.</p>
                <p>
                Data on file. Pfizer, Inc. 2022.</p>
            </div>
            </div>
            <div class="swiper-slide infections">
                <h3 class="safety-header">INFECTIONS (&gt;2% OCCURENCE) DURING DB PHASE (WK 18-44)</h3>
                <div class="content-container">
                <div class="toggle-group">
                    <h5 class="active">TOFACITINIB</h5>
                    <!-- Rounded switch -->
                    <label class="switch">
                        <input type="checkbox">
                        <span class="toggle round"></span>
                    </label>
                    <h5>PLACEBO</h5>
                </div>
                <div class="img-wrapper">
                    <img src="assets/safety/tofacitinib.svg" alt="tofacitinib" class="toggle-img"/>
                </div>
                </div>
                <div class="footnotes">
                    <p>Phase 3 safety data include full analysis set (pcJIA , jPsA , ERA patients included).</p>
                    <ol>
                        <li>5 mg BID or equivalent weight based lower dose in patients &lt;40 kg. DB=double blind</li>
                    </ol>
                    <p>BID, twice daily; DB, double-blind; ERA, enthesitis-related arthritis; jPsA, juvenile psoriatic arthritis; PBO, placebo; pcJIA, polyarticular course juvenile idiopathic arthritis; URI, upper respiratory infection.</p>
                    <p>Data on file. Pfizer Inc., New York, NY</p>
                </div>
            </div>
            <div class="swiper-slide abnormalities">
                <h3 class="safety-header">LABORATORY ABNORMALITIES</h3>
                <div class="content-container">
                <div class="img-wrapper">
                    <img src="assets/safety/safety-4.svg" alt="patients with laboratory abnormalities" />
                </div>
                </div>
                <div class="footnotes">
                    <p>Phase 3 safety data include full analysis set (pcJIA , jPsA , ERA patients included).</p>
                    <ol>
                        <li>5 mg BID or equivalent weight based lower dose in patients &lt;40 kg
                            OL=open label; DB=double blind; ALT=alanine aminotransferase; AST=aspartate aminotransferase; LLN=lower limit of normal; ULN=upper limit of normal</li>
                    </ol>
                    <p>OL, open-label; DB, double-blind; ALT, alanine aminotransferase; AST, aspartate aminotransferase; LLN, lower limit of normal; ULN, upper limit of normal; BID, twice daily; ERA, enthesitis-related arthritis;
                        jPsA, juvenile psoriatic arthritis; PBO, placebo; pcJIA, polyarticular course juvenile idiopathic arthritis.</p>
                    <p>Data on file. Pfizer Inc., New York, NY</p>
                </div>
            </div>
            <div class="swiper-slide abnormalities-cont">
                <h3 class="safety-header">LABORATORY ABNORMALITIES (CONT'D):<br> CHANGES IN LEUKOCYTES AND NEUTROPHILS</h3>
                <div class="content-container">
                <div class="img-wrapper">
                    <img src="assets/safety/safety-5.svg" alt="change from baseline" />
                </div>
                <a href="" class="recommendations">
                    <i class="fas fa-info-circle"></i> LABORATORY MONITORING RECOMMENDATIONS
                </a>
                </div>
                <div class="footnotes">
                    <ol>
                        <li>5 mg BID or equivalent weight-based lower dose in patients &lt;40 kg DB=double blind, OL=Open label</li>
                    </ol>
                    <p>BID, twice daily; DB, double-blind; OL, open-label; PBO, placebo; pcJIA, polyarticular course juvenile idiopathic arthritis.</p>
                    <p>
                        Data on file. Pfizer Inc., New York, NY
                    </p>
                </div>
            </div>
        </div>
        <div class="swiper-button-next safety">
            NEXT
        </div>
        <div class="swiper-button-prev safety">PREVIOUS</div>
        <div class="swiper-pagination safety"></div>
        </div>
        <button class="review-btn safety vis-hidden">
            <i class="fas fa-question"></i>
            <h5>REVIEW</h5>
        </button>
    </main>
</div>
    <nav class="mobile">
        <a href="" ui-sref="MOA" class="moa">
            <i class="fas fa-atom"></i>
            <h5>MOA</h5>
        </a>
        <a href="" ui-sref="CT" class="ct">
            <i class="fas fa-users"></i>
            <h5>Clinical Trials</h5>
        </a>
        <a href="" ui-sref="EFFICACY" class="efficacy">
            <i class="fas fa-chart-line"></i>
            <h5>Efficacy</h5>
        </a>
        <a href="" ui-sref="SAFETY" class="safety active">
            <i class="fas fa-exclamation-triangle"></i>
            <h5>Safety</h5>
        </a>
        <a href="" ui-sref="DOSING" class="dosing">
            <i class="fas fa-prescription"></i>
            <h5>Dosing</h5>
        </a>
    </nav>
</section>
<script src="js/safety/swiper-config.js" defer></script>
<script src="js/safety/modal.js" defer></script>
<script src="js/safety/toggle.js" defer></script>
